Denifanstat elicited a significant ≥ 2-stage improvement in fibrosis in F3 MASH patients, and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients: secondary analysis of the phase 2b FASCINATE-2 trial
MASH TAG
NASH
FASN Inhibitor Denifanstat Achieved All Endpoints in the Treatment of Acne Vulgaris: Results from a Phase III Randomised Placebo-Controlled Trial
2025 Fall Clinical Dermatology Conference
Highlighting Mechanism of Action of FASN Inhibitor Denifanstat in MASH
9th Annual MASH Drug Development Summit
Utilizing AI-Based Digital Pathology to Evaluate Denifanstat’s Anti-Fibrotic Effect in MASH Patients with Advanced Fibrosis
9th Annual MASH Drug Development Summit
First-in-Class FASN Inhibitor Denifanstat Achieved All Endpoints in the Treatment of Acne Vulgaris: Results from a Phase 3 Randomised Placebo Controlled Trial
European Academy of Dermatology and Venereology (EADV) Congress 2025
